摘要
目的:探讨特异性免疫治疗(specific immunotherapy,SIT)对哮喘大鼠白细胞介素-10(IL-10)和CD4+CD25+调节性T细胞(CD4+CD25+Tr)的影响。方法:40只健康雄性清洁级Wistar大鼠随机均分成正常对照组、哮喘组、SIT对照组和SIT治疗组,每组10只。通过卵蛋白(OVA)雾化吸入的方法对致敏大鼠进行SIT干预,观察各组支气管肺泡灌洗液(BALF)中细胞分类及计数结果、血清和BALF中IL-10水平及外周血CD4+CD25+Tr百分率变化。结果:正常对照组BALF和血清中IL-10浓度分别高于哮喘组和SIT对照组(均为P<0.01),哮喘组和SIT对照组BALF和血清中IL-10浓度低于SIT治疗组(P<0.01,P<0.05);正常对照组外周血CD4+CD25+Tr百分率显著高于哮喘组、SIT对照组和SIT治疗组(P<0.01),而SIT治疗组CD4+CD25+Tr百分率分别高于哮喘组和SIT对照组(P<0.05)。结论:通过上调体内IL-10和CD4+CD25+Tr趋于正常状态可能是SIT治疗哮喘有效的重要机制。
AIM：To approach the effect of specific immunotherapy on IL-10 and CD4＋CD25＋ regulatory T cells（CD4＋CD25＋ Tr）in asthmatic rats.METHODS：Forty Wistar rats were randomly divided into 4 groups：control group,asthma group,control of specific immunotherapy group and specific immunotherapy group,with 10 rats in each group.The model of asthma was established by the ovalbumin（OVA）challenge methods and specific immunotherapy group received specific immunotherapy by repeated inhaling different doses of OVA.The concentrations of IL-10 in BALF and serum were detected by ELISA.The percentage of CD4＋CD25＋ Tr in peripheral blood was measured by flow cytometry（FCM）.RESULTS：The concentration of IL-10 in BALF and serum of control group were higher than that of asthma group and control of specific immunotherapy group,respectively（P0.01）.The concentration of IL-10 in BALF and serum of specific immunotherapy group were higher than that of asthma group and control of specific immunotherapy group（P0.01,P0.05）.The percentage of CD4＋CD25＋ Tr in peripheral blood of control group was higher than that of asthma group,control of specific immunotherapy group and specific immunotherapy group（P0.01）.The percentage of CD4＋CD25＋ Tr in peripheral blood of specific immunotherapy group was higher than that of asthma group and control of specific immunotherapy group（P0.05）.CONCLUSION：Specific immunotherapy can up-regulate the expressions of IL-10 and CD4＋CD25＋ Tr in asthmatic rats.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2010年第8期871-875,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
浙江省医药卫生科技计划项目(2008B192)
台州市科技局课题(061KY06)
